All World

H1N1 Vaccines: Sanofi Pasteur willing to renegotiate his contract

Four laboratories were sold to the French government 94 million doses of vaccine against influenza A. This is the British GSK for 50 million doses from Sanofi Pasteur French (28 million doses), Swiss Novartis (16 million) and the U.S. Baxter (50 000 doses). All these quantities have not yet been delivered for lack of sufficient production capacity. And even if the needs now seem to have been overstated, these manufacturers have no plans so far to suspend deliveries.

"For now, we have delivered half of our 28 million doses, which is consistent with our commitments, Le Figaro said a spokesman for Sanofi Pasteur. And we will continue to stagger our deliveries as agreed until March. The government has not contacted us to ask us to consider something else. "Contacts, GSK and Novartis did not respond to our calls on Sunday.

675 million euros

Legally, it seems very difficult to challenge a contract by tender procedure if it is binding. The economic and political reality of things can push the labs to be conciliatory, given the weight of government on drugs: is the State which sets prices, and Medicare which, directly or indirectly, pays! Sanofi-Pasteur – French group which is more … – said he also "willing to renegotiate if the government asked," even if "no clause in the contract so provides."

Sanofi-Pasteur's vaccine bill without adjuvant dose 6.25 euros; GSK, 7 euros, Novartis, EUR 9.34; Baxter, 10 euros. Overall, the market rises and to 675 million euros.Besides the 36 million doses that the government had pr?r?serv?es, where the 94 million departure would not have been enough! Manufacturers have realized that they could make a cross on the command there.

Another beneficiary of influenza A, Roche, who with treatment Tamiflu, which reduces the duration of the flu, "has been a more important," admits one in the Swiss group. But in this case, the stock of government has been gradually established since 2003, with 33 million doses of which 24 million treatments of Tamiflu and 11 million treatment courses of Relenza (GSK).

ALSO READ

"SPECIAL – All about the influenza A

"Same problem for Tamiflu and masks

"Influenza A (H1N1): the difficulty in France sell its vaccines